Clinical Trial Update: Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) [Phase 1, Phase 2]

View source ↗

Summary

Dose escalation trial of CM310 in adults with moderate-to-severe atopic dermatitis has completed Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CM310

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Moderate-to-severe Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED